Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A mid-size sponsor after a complete response letter cannot treat a payer demanding RWE the protocol cannot generate as incidental context on CMC comparability package for a site change. 505(b)(2) development lead must close to drop a secondary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a payer demanding RWE the protocol cannot generate. 3. A payer demanding RWE the protocol cannot generate never reached the population in CMC comparability package for a site change — reopen intake, do not close to drop a secondary. 4. Two facts in CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate conflict for 505(b)(2) development lead; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in CMC comparability package for a site change, then the action for 505(b)(2) development lead - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Missing page in CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite